Sun Pharma Canada is excited to announce the launch of CEQUA, a new treatment option for moderate to severe keratoconjunctivitis sicca.
Formulated with nanomicelle technology, CEQUA (cyclosporine ophthalmic solution, 0.09% w/v) is indicated to increase tear production in patients with moderate to severe keratoconjunctivitis sicca (dry eye).
In the pivotal, phase 3 confirmatory study in which 744 patients with dry eye were treated either with CEQUA or its vehicle, CEQUA showed a statistically significant improvement in the primary endpoint, percentage of patients with an increase of at least 10 mm in Schirmer’s score at 12 weeks vs vehicle. Additionally, CEQUA was associated with statistically significant improvements in both corneal and conjunctival staining. Improvement in total corneal staining was evident as early as one month. CEQUA was generally well tolerated with most adverse events considered to be mild and not requiring treatment.
Comments